Skip to main content

Table 3 Pairwise treatment comparisons from network meta-analyses for the outcomes post-treatment depression scores (above the diagonal) and study discontinuation (below the diagonal)

From: Comparative effectiveness of psychological treatments for depressive disorders in primary care: network meta-analysis

Ftf CBT

0.18

0.21

0.00

0.02

−0.02

−0.16

−0.04

0.06

−1.31

−0.17

0.08

0.05

0.11

−0.02

0.34

−0.09–0.44

−0.07–0.50

−0.66–0.67

−0.21–0.25

−0.25–0.20

−0.88–0.55

−0.31–0.22

−0.20–0.33

−2.15–(−0.47)

−0.69–0.35

−0.29–0.46

−0.22–0.32

−0.19–0.41

−0.56–0.53

0.16–0.51

1.47

Ftf PST

0.04

−0.17

−0.16

−0.20

−0.34

−0.22

−0.11

−1.48

−0.35

−0.09

−0.13

−0.06

−0.19

0.16

0.65–3.51

−0.23–0.31

−0.81–0.47

−0.42–0.11

−0.48–0.08

−1.06–0.38

−0.50–0.06

−0.39–0.17

−2.31–(−0.66)

−0.81–0.12

−0.44–0.25

−0.34–0.09

−0.36–0.24

−0.76–0.37

−0.04–0.36

0.98

0.67

Ftf IPT

−0.21

−0.19

−0.24

−0.38–1.11–

−0.26

−0.15

−1.52

−0.38

−0.13

−0.16

−0.10

−0.23

0.12

0.30–3.11

0.25–1.70

−0.86–0.44

−0.48–0.09

−0.54–0.06

0.35

−0.56–0.05

−0.45–0.15

−2.36–(−0.69)

−0.90–0.14

−0.44–0.17

−0.41–0.08

−0.40–0.19

−0.81–0.34

−0.11–0.35

1.72

1.17

1.75

Ftf PDT

0.02

−0.03

−0.17

−0.05

0.06

−1.31

−0.17

0.08

0.05

0.11

−0.02

0,33

0.24–15.2

0.18–9.32

0.25–14.41

−0.65–0.68

−0.70–0.64

−1.11–0.78

−0.72–0.62

−0.61–0.73

−2.31–(−0.31)

−0.95–0.60

−0.60–0.75

−0.56–0.65

−0.57–0.79

−0.85–0.81

−0,31–0,97

0.99

0.67

1.01

0.58

Ftf Other

−0.04

−0.19

−0.06 –0.33–

0.04

−1.33

−0.19

0.06

0.03

0.09

−0.04

0.31

0.48–2.12

0.27–1.59

0.34–3.07

0.07–4.46

−0.30–0.21

−0.90–0.53

0.20

−0.22–0.30

−2.17–(−0.49)

−0.71–0.33

−0.31–0.43

−0.24–0.30

−0.20–0.39

−0.54–0.46

0.14–0.49

1.75

1.19

1.79

1.02

1.77

Rtl CBT

−0.14

−0.02

0.09

−1.29

−0.15

0.11

0.07

0.14

0.01

0.36

0.67–4.46

0.36–3.51

0.50–6.34

0.09–7.89

0.59–5.14

−0.86–0.58

−0.30–0.26

−0.19–0.36

−2.13–(−0.44)

−0.68–0.38

−0.28–0.49

−0.21–0.36

−0.18–0.45

−0.55–0.57

0.17–0.55

0.74

0.51

0.76

0.43

0.75

0.42

Rtl PST

0.12

0.23

−1.14

0.00

0.25

0.22

0.28

0.15

0.50

0.17–3.23

0.11–2.22

0.15–3.32

0.04–4.66

0.18–3.21

0.08–2.17

−0.60–0.84

−0.49–0.95

−2.22–(−0.07)

−0.86–0.85

−0.52–1.02

−0.51–0.94

−0.46–1.02

−0.72–1.02

−0.19–1.19

0.62

0.42

0.63

0.36

0.63

0.35

0.83

Gsh CBT

0.11

−1.26

−0.13

0.13

0.09

0.16

0.03

0.38

0.24–1.46

0.16–1.00

0.20–1.88

0.04–2.81

0.25–1.56

0.11–1.08

0.19–3.80

−0.17–0.39

−2.11–(−0.42)

−0.66–0.41

−0.26–0.51

−0.20–0.38

−0.17–0.48

−0.54–0.59

0.18–0.58

0.66

0.45

0.68

0.39

0.67

0.38

0.89

1.07

Nmc CBT

−1.37

−0.23

0.02

−0.01

0.05

−0.08 –0.64–

0.27

0.21–2.08

0.15–1.37

0.19–2.16

0.04–3.48

0.23–1.96

0.102–1.43

0.18–4.43

0.35–3.46

−2.22–(−0.53)

−0.76–0.30

−0.37–0.40

−0.30–0.2

−0.27–0.37

0.48

0.07–0.47

No data

No data

No data

No data

No data

No data

No data

No data

No data

Ftf CBT + SSRI

1.14

1.39

1.36

1.42

1.29

1.64

0.21–2.07

0.54–2.24

0.56–2.16

0.57–2.27

0.31–2.27

0.82–2.47

2.04

1.39

2.08

1.19

2.06

1.16

2.74

3.29

3.07

No data

Ftf PST + SSRI

0.25

0.22

0.28

0.15

0.50

0.40–9.99

0.34–5.61

0.40–10.65

0.12–12.2

0.40–9.90

0.20–6.44

0.31–20.2

0.65–18.1

0.56–16.7

−0.31–0.81

−0.26–0.70

−0.26–0.82

−0.57–0.88

0.01–1.00

1.54

1.05

1.58

0.90

1.56

0.88

2.07

2.49

2.32

No data

0.76

Ftf IPT + SSRI

−0.03

0.03

−0.10

0.25

0.38–6.64

0.29–4.04

0.50–5.10

0.09–7.19

0.39–6.64

0.18–4.16

0.33–13.7

0.55–10.5

0.48–12.5

0.13–4.68

−0.33–0.27

−0.36–0.42

−0.72–0.53

−0.08–0.58

1.26

0.86

1.29

0.73

1.27

0.72

1.69

2.03

1.90

No data

0.62

0.82

SSRI

0.06

−0.07

0.28

0.52–3.18

0.44–1.76

0.53–3.20

0.11–4.10

0.51–3.45

0.22–2.39

0.39–8.14

0.74–5.83

0.60–6.77

0.16–3.11

0.26–2.73

−0.24–0.37

−0.64–0.50

0.08–0.49

1.54

1.05

1.58

0.90

1.56

0.88

2.08

2.49

2.33

No data

0.76

1.00

1.23

TCA

−0.13

0.22

0.45–5.36

0.37–3.10

0.57–4.37

0.09–7.67

0.50–5.56

0.22–3.54

0.40–11.0

0.70–9.17

0.70–9.57

0.13–4.10

0.23–4.25

0.39–3.90

−0.71–0.45

−0.03–0.48

2.01

1.37

2.06

1.17

2.03

1.15

2.71

3.25

3.04

No data

0.99

1.31

1.60

1.30

Individ.. Antid.

0.35

0.40–9.46

0.25–7.50

0.32–11.74

0.08–12.9

0.46–8.52

0.18–6.73

0.35–19.8

0.57–18.5

0.47–18.4

0.10–9.23

0.17–9.78

0.26–8.45

0.21–8.41

−0.18–0.88

1.00

0.68

1.03

0.59

1.01

0.57

1.35

1.62

1.51

No data

0.49

0.65

0.80

0.65

0.50

UC/placebo

0.57–1.86

0.34–1.27

0.40–2.39

0.08–4.08

0.56–1.86

0.22–1.45

0.36–5.16

0.80–3.24

0.60–3.76

0.11–2.22

0.18–2.33

0.36–1.60

0.21–1.76

0.11–2.48

  1. With regard to post-treatment depression scores, standardized mean differences above 0 favor the row-defining treatment, and below 0 the column-defining treatment. With regard to study discontinuation, odds ratios smaller than 1 favor the column-defining treatment, and odds ratios lower than 1 favor the row-defining treatment. Reciprocals should be used to obtain odds ratios in the opposite direction. Bold-faced figures indicate a difference between treatments with 95 % credible intervals of estimates excluding 1. For abbreviations see Table 2
  2. The results are standardized mean differences (post-treatment depression scores with 95 % confidence intervals) and odds ratios (study discontinuation with 95 % credible intervals) when comparing the column-defined treatments with the row-defined treatments